CHICAGO / Sep 18, 2023 / Business Wire / GE HealthCare (Nasdaq: GEHC) today announced it received a grant from the Bill & Melinda Gates Foundation for more than $44 million to create user-friendly, artificial intelligence (AI)-assisted ultrasound imaging auto-assessment tools. These tools will seek to aid healthcare professionals—even those without specialized training or experience with ultrasound—with clinical decision information to support more effective obstetric and lung screening ultrasound scans across maternal and fetal care as well as pediatric lung health, with a goal of expanding access to low-and-middle income countries (LMIC) and across diverse sites of care.
Caption Health, a leader in medical AI acquired by GE HealthCare in February 2023, will design this technology to run across a range of ultrasound devices and probes, including lower-cost handheld devices.
“We are proud and excited to have received this grant from the Bill & Melinda Gates Foundation to make ultrasound more accessible in low-and-middle income countries. Ultrasound is an essential tool for screening and diagnosis of various medical conditions, including the health of expectant mothers and managing respiratory diseases,” said Roland Rott, President and CEO, Ultrasound, GE HealthCare. “However, a key limitation is the guidance of lesser-skilled users to effectively apply affordable point-of-care ultrasound in their care environment. This grant will help bring Caption Health’s leading AI technology customized to more users, and therefore contribute to increased access to higher-quality medical care.”
Maternal and child mortality is a critical healthcare issue around the world. In 2020, almost 800 women died every day from preventable causes linked to pregnancy and childbirth, with approximately 95 percent of all maternal deaths occurring in LMIC.1 In 2019, 2.4 million children around the world died in their first month of life. Ultrasound technologies are used in maternal care to determine fetal health markers and conditions like gestational age, fetal presentation, multiple gestation (more than one fetus), fetal viability, umbilical blood flow, and ectopic pregnancy.
For children younger than five years old, pneumonia is the leading cause of death worldwide.2 Because symptoms of pneumonia can develop suddenly, early diagnosis is vital to effective treatment and preventing complications. Point of care lung ultrasound can provide physicians with a view of the entire lung, is easily repeatable and can diagnose pneumonia with greater accuracy compared with a bedside chest X-ray.3
In 2020, Caption Health received a grant from the Bill & Melinda Gates Foundation to support the development of innovative AI technology for lung ultrasound.
“Caption Health AI applications are designed to guide healthcare professionals, step-by-step, during an ultrasound exam to help them capture and interpret high-quality ultrasound images,” said Karley Yoder, Chief Digital Officer, Ultrasound, GE HealthCare and General Manager, Caption Health. “We are thankful for the continued support of the Bill & Melinda Gates Foundation, which enables us to expand the development of our existing lung ultrasound project and also broaden the reach of this powerful, novel technology to help provide care to mothers and children.”
Currently, Caption Health offers Cardiac Guidance software, which is FDA cleared. With the support of the Bill & Melinda Gates Foundation grant, Caption Health will develop multiple lung ultrasound and obstetric algorithms through clinical validation and regulatory submissions.
About GE HealthCare
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are an $18.3 billion business with 50,000 employees working to create a world where healthcare has no limits.
Follow us on Facebook, LinkedIn, Twitter, Instagram and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.
1 World Health Organization. Maternal Mortality. Published February 22, 2023. Accessed August 22, 2023. Available at: https://www.who.int/news-room/fact-sheets/detail/maternal-mortality.
2 World Health Organization. Pneumonia. WHO. https://www.who.int/news-room/fact-sheets/detail/pneumonia. Accessed June 10, 2022.
3 Systematic review and meta-analysis for the use of ultrasound versus radiology in diagnosing of pneumonia, Saeed Ali Alzahrani et al. Crit Ultrasound J. 2017; 9: 6. doi: 10.1186/s13089-017-0059-y
Last Trade: | US$77.09 |
Daily Change: | -2.16 -2.73 |
Daily Volume: | 3,055,620 |
Market Cap: | US$35.220B |
December 05, 2024 December 03, 2024 December 01, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB